Actinogen Medical Ltd (ACW)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Actinogen Medical Ltd (ACW) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013163
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Actinogen Medical Ltd (Actinogen), formerly Actinogen Ltd is a biotechnology company that undertakes research in Alzheimer’s disease and other chronic neurodegenerative diseases. The company’s xanamem is a novel drug under development for the treatment of Alzheimer’s disease. It develops drug to treat other age-related neurodegenerative diseases. Actinogen is also developing drugs for diabetes, post traumatic stress disorder, cognitive dysfunction in schizophrenia and depression and cardiovascular disease. The company undertakes various other clinical trials. It partners with other research companies for its clinical trials. Actinogen is headquartered in Sydney, Western Australia, Australia.

Actinogen Medical Ltd (ACW) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Actinogen Medical Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Actinogen Medical Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Actinogen Medical Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Actinogen Medical Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Actinogen Medical Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Actinogen Medical Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Actinogen Prices Rights Offering of Shares for USD1 Million 10
Actinogen Raises USD8 Million in Private Placement of Shares 11
Actinogen Completes Private Placement Of Shares For US$1.4 Million 12
Actinogen Completes Private Placement Of Shares For US$0.06 Million 13
Actinogen Withdraws Rights Offering Of Shares For US$0.5 Million 14
Acquisition 15
Actinogen Acquires Corticrine 15
Actinogen Acquires Celgenics 16
Actinogen Medical Ltd – Key Competitors 17
Actinogen Medical Ltd – Key Employees 18
Actinogen Medical Ltd – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Financial Announcements 20
Oct 30, 2017: Actinogen Medical: September Quarterly Update 20
Corporate Communications 22
Aug 14, 2017: Actinogen Medical announces Resignation of Director 22
Nov 30, 2016: Actinogen Medical: Retirement of Martin Rogers as Chairman of Actinogen Medical 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Actinogen Medical Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Actinogen Medical Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Actinogen Medical Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Actinogen Medical Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Actinogen Medical Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Actinogen Medical Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Actinogen Prices Rights Offering of Shares for USD1 Million 10
Actinogen Raises USD8 Million in Private Placement of Shares 11
Actinogen Completes Private Placement Of Shares For US$1.4 Million 12
Actinogen Completes Private Placement Of Shares For US$0.06 Million 13
Actinogen Withdraws Rights Offering Of Shares For US$0.5 Million 14
Actinogen Acquires Corticrine 15
Actinogen Acquires Celgenics 16
Actinogen Medical Ltd, Key Competitors 17
Actinogen Medical Ltd, Key Employees 18
Actinogen Medical Ltd, Subsidiaries 19

★海外企業調査レポート[Actinogen Medical Ltd (ACW)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Keane Group Inc (FRAC):石油・ガス:M&Aディール及び事業提携情報
    Summary Keane Group Inc (Keane Group) is an oil and gas company that offers integrated completion and drilling services. The company provides hydraulic fracturing services, engineered solutions, wire-line services, pressure pumping, cementing service, coiled tubing and well intervention services. It …
  • MedSynergies Inc:医療機器:M&Aディール及び事業提携情報
    Summary MedSynergies Inc (MedSynergies), a subsidiary of Optum Inc, is a healthcare service provider that offers services in business aspects of medicine. The company offers revenue cycle management, consulting services, practice management, business process analysis and software integration solutio …
  • Thor Mining Plc (THR):企業の財務・戦略的SWOT分析
    Summary Thor Mining Plc (Thor Mining) is a mining and mineral exploration and development company. The company carries out acquisition, exploration and develops gold, tungsten and molybdenum properties. Its projects include Molyhil Tungsten and Molybdenum, Spring Hill Gold, Dundas Gold project, and …
  • Kadimastem Ltd (KDST):製薬・医療:M&Aディール及び事業提携情報
    Summary Kadimastem Ltd (Kadimastem) is a clinical stage biopharmaceutical company that develops industrial regenerative medicines to treat neuro-degenerative diseases. Its technology platform enables the manufacturing of islet-like endocrine cells (differentiated cells) and glia restricted progenito …
  • Kin and Carta plc (KCT):企業の財務・戦略的SWOT分析
    Kin and Carta plc (KCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • KB Home:企業の戦略・SWOT・財務情報
    KB Home - Strategy, SWOT and Corporate Finance Report Summary KB Home - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • National Bank Of Kuwait Sak
    National Bank Of Kuwait Sak - Strategy, SWOT and Corporate Finance Report Summary National Bank Of Kuwait Sak - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Cleveland BioLabs Inc (CBLI)-医療機器分野:企業M&A・提携分析
    Summary Cleveland BioLabs Inc (Cleveland) is a biopharmaceutical company that develops and commercializes drugs to treat cancer, orphan indications and protect healthy tissues from radiation and chemotherapy. The company’s product includes entolimod, a recombinant protein which acts as an agonist of …
  • Virginia Electric and Power Company:企業の発電所・SWOT分析2018
    Virginia Electric and Power Company - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Aiful Corp:企業の戦略・SWOT・財務分析
    Aiful Corp - Strategy, SWOT and Corporate Finance Report Summary Aiful Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Reliance Infrastructure Ltd (RELINFRA):企業の財務・戦略的SWOT分析
    Reliance Infrastructure Ltd (RELINFRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Eris Lifesciences Ltd (ERIS):製薬・医療:M&Aディール及び事業提携情報
    Summary Eris Lifesciences Ltd (Eris Lifesciences) is a health care products and service provider. The company offers glimepride, telmisertan, methylcobalamin and combinations, vitamin d, rabeprazole, olmesartan, mecobalamin colecalciferol, teneligliptin, rosa canina extract, cilnidipine, atorvastati …
  • Petrosibir AB (SHEL B):企業の財務・戦略的SWOT分析
    Summary Petrosibir AB (Petrosibir) formerly Shelton Petroleum AB, is an oil and gas company. The company offers exploration and development of oil and gas assets and the resource-rich basins in Russia and Ukraine. It holds Ayazovskoye production license and Rustamovskoye exploration license that cov …
  • Boryung Medience Corp:企業の戦略・SWOT・財務分析
    Boryung Medience Corp - Strategy, SWOT and Corporate Finance Report Summary Boryung Medience Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Laboratory Corp of America Holdings (LH)-製薬・医療分野:企業M&A・提携分析
    Summary Laboratory Corp of America Holdings (LabCorp) is a provider of clinical laboratory services and end-to-end drug development support. It focuses on the development and commercialization of a wide range of diagnostic technologies and testing services. The company offers clinical diagnostics la …
  • MetaStat Inc (MTST):医療機器:M&Aディール及び事業提携情報
    Summary MetaStat Inc (MetaStat) is a biotechnology company that discovers and develops personalized diagnostic and therapeutic treatment solutions for cancer patients. The company develops therapeutic product candidates based on novel approach that offers intracellular Mena protein isoforms drugable …
  • Hanwha Chemical Corp (009830):企業の財務・戦略的SWOT分析
    Summary Hanwha Chemical Corp (Hanwha), a subsidiary of Hanwha Corp is a chemical company that manufactures, develops, and distributes basic industrial chemicals, general purpose plastic products, and other chemical products. The company's chemical products include inorganic compounds, PVC, polymers, …
  • Puma Biotechnology Inc (PBYI):製薬・医療:M&Aディール及び事業提携情報
    Summary Puma Biotechnology Inc (Puma) is a biopharmaceutical company that develops novel therapeutics for the treatment of cancer. The company develops and commercializes three drug candidates, namely, PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Its pipeline portfolio also enc …
  • Cyprotex Ltd-医療機器分野:企業M&A・提携分析
    Summary Cyprotex Ltd (Cyprotex), a subsidiary of Evotec AG is a provider of ADME-Tox contract research services. It provides these services to the biotechnology, pharmaceutical, cosmetics/personal care and chemical industries. The company’s core capabilities include high quality mechanistic toxicolo …
  • Golden Meditech Holdings Ltd (801):製薬・医療:M&Aディール及び事業提携情報
    Summary Golden Meditech Holdings Ltd (Golden Meditech) is a medical equipment provider that provides blood stem cells storage and hospital management solutions. The company provides autologous blood recovery systems. It offers hospital management, medical insurance administration and blood bank serv …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆